Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03 2022 - 7:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced that
Bruce Goldsmith, Ph.D., president, and chief executive officer,
will present at the 40th Annual J.P. Morgan Healthcare Conference
being held virtually on Monday, January 10, 2022 at 10:30 a.m. ET.
A live webcast of the event will be available on the Investors
& Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentation will be
available for 30 days following the event.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide
life-transforming genetic medicines for patients with CNS diseases
that replace their suffering with boundless possibility, all while
building lasting relationships with the communities we serve. Based
in Philadelphia, PA, our company has established a strategic
collaboration and licensing agreement with the renowned University
of Pennsylvania’s Gene Therapy Program to conduct our discovery and
IND-enabling preclinical work. This provides our team with enhanced
access to a broad portfolio of gene therapy candidates and future
gene therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies into
clinical testing. As we work with speed and tenacity, we are always
mindful of patients who may be able to benefit from our therapies.
More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart HendersonPassage
Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:
Gwen FisherPassage
Bio215-407-1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2023 to Jul 2024